FDA has decided to join the real world next year – or at least, explore it, in terms of what type of data it will consider from innovator drug makers.
Under negotiations with the innovator biopharmaceutical community for the sixth round of the reauthorization of the Prescription Drug User Fee...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?